Skip to main content
News

Growing popularity of virtual biotechs promises boon to outsourcers – FierceCRO

By March 23, 2012No Comments
NewImage

NewImage

The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire ($SHPGY) has helped spotlight the growing popularity of the virtual biotech model. And that has big implications for everyone in the outsourcing industry.

Like other virtuals–such as Stromedix, recently acquired by Biogen Idec ($BIIB)–FerroKin had only a handful of employees working full-time for the company. CROs, CMOs and other outsourcers created a network of support vendors that carried out much of the heavy lifting in drug research. And with some proof of concept data in hand, FerroKin made a tantalizing morsel for an acquirer looking to build up its pipeline without having to acquire a sizable research infrastructure it didn’t need.

{iframe}http://www.fiercecro.com/story/growing-popularity-virtual-biotechs-promises-boon-outsourcers/2012-03-22{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.